Customer publications – B-705

← Return to all publications

2021

1. J. Yang, C. Zhao, J. Lim, L. Zhao, R. L. Tourneau, Q. Zhang, D. Dobson, S. Joshi, J. Pang, X. Zhang, S. Pal, C. Andreou, H. Zhang, M. F. Kircher, H. Schmitthenner. Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging

   Theranostics, vol. 11, 2021, pp. 2534-2549
   

2. Y. Wang, H. Ni, S. Zhou, K. He, Y. Gao, W. Wu, M. Wu, Z. Wu, X. Qiu, Y. Zhou, B. Chen, D. Pan, C. Huang, M. Li, Y. Bian, M. Yang, L. Miao, J. Liu. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

   Cancer Immunol Immunother, vol. 70, 2021, pp. 365-376
   

3. F. Simonetta, I. S. Alam, J. K. Lohmeyer, B. Sahaf, Z. Good, W. Chen, Z. Xiao, T. Hirai, L. Scheller, P. Engels, O. Vermesh, E. Robinson, T. Haywood, A. Sathirachinda, J. Baker, M. B. Malipatlolla, L. M. Schultz, J. Y. Spiegel, J. T. Lee, D. B. Miklos, C. L. Mackall, S. S. Gambhir, R. S. Negrin. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET

   Clin Cancer Res, vol. 27, 2021, pp. 1058-1068
   

4. J. Ren, M. Xu, J. Chen, J. Ding, P. Wang, L. Huo, F. Li, Z. Liu. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷Lu-labeled αPD-L1 antibody

   Theranostics, vol. 11, 2021, pp. 304-315
   

5. A. Gonzalez-Junca, O. Reiners, L. D. Borrero-Garcia, D. Beckford-Vera, A. A. Lazar, W. Chou, S. Braunstein, H. VanBrocklin, B. L. Franc, M. H. Barcellos-Hoff. Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors

   Int J Radiat Oncol Biol Phys, vol. 109, 2021, pp. 527-539
   

6. P. Diebolder, C. Mpoy, J. Scott, T. T. Huynh, R. Fields, D. Spitzer, N. Bandara, B. E. Rogers. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44

   J Nucl Med, vol. 62, 2021, pp. 137-143
   

7. A. Cavaliere, S. Sun, S. Lee, J. Bodner, Z. Li, Y. Huang, S. L. Moores, B. Marquez-Nostra. Development of ⁸⁹ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer

   Eur J Nucl Med Mol Imaging, vol. 48, 2021, pp. 383-394
   

8. I. J. G. Burvenich, Y. W. Goh, N. Guo, H. K. Gan, A. Rigopoulos, D. Cao, Z. Liu, U. Ackermann, C. W. Wichmann, A. F. McDonald, N. Huynh, G. J. O\'Keefe, S. J. Gong, F. E. Scott, L. Li, W. Geng, A. Zutshi, Y. Lan, A. M. Scott. Radiolabelling and preclinical characterization of (89)Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa

   Eur J Nucl Med Mol Imaging, vol. 48, 2021, pp. 3075-3088
   

2020

9. Z. Xiao, A. T. Mayer, T. W. Nobashi, S. S. Gambhir. ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy

   Cancer Res, vol. 80, 2020, pp. 3023-3032
   

10. G. A. Ulaner, N. B. Sobol, J. A. O'Donoghue, A. S. Kirov, C. C. Riedl, R. Min, E. Smith, L. M. Carter, S. K. Lyashchenko, J. S. Lewis, C. O. Landgren. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging

    Radiology, vol. 295, 2020, pp. 606-615
    

11. R. Tang, A. Zheleznyak, M. Mixdorf, A. Ghai, J. Prior, K. C. L. Black, M. Shokeen, N. Reed, P. Biswas, S. Achilefu. Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma

    ACS Nano, vol. 14, 2020, pp. 4255-4264
    

12. M. L. Senders, A. E. Meerwaldt, M. M. T. van Leent, B. L. Sanchez-Gaytan, J. C. van de Voort, Y. C. Toner, A. Maier, E. D. Klein, N. A. T. Sullivan, A. M. Sofias, H. Groenen, C. Faries, R. S. Oosterwijk, E. M. van Leeuwen, F. Fay, E. Chepurko, T. Reiner, R. Duivenvoorden, L. Zangi, R. M. Dijkhuizen, S. Hak. Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging

    Nat Nanotechnol, vol. 15, 2020, pp. 398-405
    

13. P. M. R. Pereira, K. Mandleywala, A. Ragupathi, J. S. Lewis. Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors

    Clin Cancer Res, vol. 26, 2020, pp. 6215-6229
    

14. E. Peplau, F. De Rose, S. Reder, M. Mittelhäuser, G. Scafetta, M. Schwaiger, W. A. Weber, A. Bartolazzi, A. Skerra, C. D\'Alessandria. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer

    Thyroid, vol. 30, 2020, pp. 1314-1326
    

15. N. Pandit-Taskar, M. A. Postow, M. D. Hellmann, J. J. Harding, C. A. Barker, J. A. O\'Donoghue, M. Ziolkowska, S. Ruan, S. K. Lyashchenko, F. Tsai, M. Farwell, T. C. Mitchell, R. Korn, W. Le, J. S. Lewis, W. A. Weber, D. Behera, I. Wilson, M. Gordon, A. M. Wu, J. D. Wolchok. First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

    J Nucl Med, vol. 61, 2020, pp. 512-519
    

16. Jacm Goos, A. Cho, L. M. Carter, T. R. Dilling, M. Davydova, K. Mandleywala, S. Puttick, A. Gupta, W. S. Price, J. F. Quinn, M. R. Whittaker, J. S. Lewis, T. P. Davis. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect

    Theranostics, vol. 10, 2020, pp. 567-584
    

17. C. Christensen, L. K. Kristensen, M. Z. Alfsen, C. H. Nielsen, A. Kjaer. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody

    Eur J Nucl Med Mol Imaging, vol. 47, 2020, pp. 1302-1313
    

18. M. Chomet, M. Schreurs, M. Nguyen, B. Howng, R. Villanueva, M. Krimm, O. Vasiljeva, Gams van Dongen, D. J. Vugts. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹Zr-immuno-PET in xenograft bearing mice

    Theranostics, vol. 10, 2020, pp. 5815-5828
    

19. E. Berg, H. Gill, J. Marik, A. Ogasawara, S. Williams, G. van Dongen, D. Vugts, S. R. Cherry, A. F. Tarantal. Total-Body PET and Highly Stable Chelators Together Enable Meaningful ⁸⁹Zr-Antibody PET Studies up to 30 Days After Injection

    J Nucl Med, vol. 61, 2020, pp. 453-460
    

20. D. R. Beckford Vera, S. D. Fontaine, H. F. VanBrocklin, B. R. Hearn, R. Reid, G. W. Ashley, D. V. Santi, B. Bengsch, T. Ohtani, O. Khan, M. Setty, S. Manne, S. O'Brien, P. F. Gherardini, R. S. Herati, A. C. Huang, K. M. Chang, E. W. Newell, N. Bovenschen, D. Pe'er, S. M. Albelda, E. J. Wherry. PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89

    Mol Cancer Ther, vol. 19, 2020, pp. 673-679
    

2019

21. Z. Yang, Y. Dai, L. Shan, Z. Shen, Z. Wang, B. C. Yung, O. Jacobson, Y. Liu, W. Tang, S. Wang, L. Lin, G. Niu, P. Huang, X. Chen. Tumour microenvironment-responsive semiconducting polymer-based self-assembly nanotheranostics

    Nanoscale Horiz, vol. 4, 2019, pp. 426-433
    

22. W. Wei, D. Jiang, Z. T. Rosenkrans, T. E. Barnhart, J. W. Engle, Q. Luo, W. Cai. HER2-targeted multimodal imaging of anaplastic thyroid cancer

    Am J Cancer Res, vol. 9, 2019, pp. 2413-2427
    

23. J. Riegler, H. Gill, A. Ogasawara, M. Hedehus, V. Javinal, J. Oeh, G. Z. Ferl, J. Marik, S. Williams, D. Sampath, J. Schartner, R. A. D. Carano. VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models

    Neoplasia, vol. 21, 2019, pp. 1036-1050
    

24. P. M. R. Pereira, K. Mandleywala, A. Ragupathi, L. M. Carter, Jacm Goos, Y. Y. Janjigian, J. S. Lewis. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors

    J Nucl Med, vol. 60, 2019, pp. 1569-1578
    

25. D. N. Pandya, N. B. Bhatt, F. Almaguel, S. Rideout-Danner, H. D. Gage, K. K. Solingapuram Sai, T. J. Wadas. ⁸⁹Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo

    J Nucl Med, vol. 60, 2019, pp. 696-701
    

26. C. Lohrmann, E. M. O'Reilly, J. A. O'Donoghue, N. Pandit-Taskar, J. A. Carrasquillo, S. K. Lyashchenko, S. Ruan, R. Teng, W. Scholz, P. W. Maffuid, J. S. Lewis, W. A. Weber. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer

    Clin Cancer Res, vol. 25, 2019, pp. 7014-7023
    

27. M. Li, D. Jiang, T. E. Barnhart, T. Cao, J. W. Engle, W. Chen, W. Cai. Immuno-PET imaging of VEGFR-2 expression in prostate cancer with ⁸⁹Zr-labeled ramucirumab

    Am J Cancer Res, vol. 9, 2019, pp. 2037-2046
    

28. W. G. Lesniak, C. Chu, A. Jablonska, Y. Du, M. G. Pomper, P. Walczak, M. Janowski. A Distinct Advantage to Intraarterial Delivery of ⁸⁹Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier

    J Nucl Med, vol. 60, 2019, pp. 617-622
    

29. W. G. Lesniak, C. Chu, A. Jablonska, B. Behnam Azad, O. Zwaenepoel, M. Zawadzki, A. Lisok, M. G. Pomper, P. Walczak, J. Gettemans, M. Janowski. PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration

    Eur J Nucl Med Mol Imaging, vol. 46, 2019, pp. 1940-1951
    

30. H. J. Lee, E. B. Ehlerding, D. Jiang, T. E. Barnhart, T. Cao, W. Wei, C. A. Ferreira, P. Huang, J. W. Engle, W. Cai. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection

    Am J Cancer Res, vol. 9, 2019, pp. 1454-1468
    

31. L. K. Kristensen, C. Fröhlich, C. Christensen, M. C. Melander, T. T. Poulsen, G. R. Galler, J. Lantto, I. D. Horak, M. Kragh, C. H. Nielsen, A. Kjaer. CD4(+) and CD8a(+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models

    Theranostics, vol. 9, 2019, pp. 8221-8238
    

32. L. K. Kristensen, C. Christensen, M. M. Jensen, B. J. Agnew, C. Schjöth-Frydendahl, A. Kjaer, C. H. Nielsen. Site-specifically labeled ⁸⁹Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model

    Theranostics, vol. 9, 2019, pp. 4409-4420
    

33. K. E. Henry, M. M. Dacek, T. R. Dilling, J. D. Caen, I. L. Fox, M. J. Evans, J. S. Lewis. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer

    Clin Cancer Res, vol. 25, 2019, pp. 166-176
    

34. N. Dmochowska, W. Tieu, M. D. Keller, H. R. Wardill, C. Mavrangelos, M. A. Campaniello, P. Takhar, P. A. Hughes. Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis

    J Nucl Med, vol. 60, 2019, pp. 858-863
    

35. D. Chen, Y. Zhou, D. Yang, M. Guan, M. Zhen, W. Lu, M. E. Van Dort, B. D. Ross, C. Wang, C. Shu, H. Hong. Positron Emission Tomography/Magnetic Resonance Imaging of Glioblastoma Using a Functionalized Gadofullerene Nanoparticle

    ACS Appl Mater Interfaces, vol. 11, 2019, pp. 21343-21352
    

2018

36. J. T. Yoon, M. S. Longtine, B. V. Marquez-Nostra, R. L. Wahl. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with ⁸⁹Zr in Human Lymphoma Xenografts

    J Nucl Med, vol. 59, 2018, pp. 1219-1224
    

37. G. A. Ulaner, S. K. Lyashchenko, C. Riedl, S. Ruan, P. B. Zanzonico, D. Lake, K. Jhaveri, B. Zeglis, J. S. Lewis, J. A. O\'Donoghue. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer

    J Nucl Med, vol. 59, 2018, pp. 900-906
    

38. W. K. Tsai, K. A. Zettlitz, R. Tavaré, N. Kobayashi, R. E. Reiter, A. M. Wu. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody

    Theranostics, vol. 8, 2018, pp. 5903-5914
    

39. F. Romero Pastrana, J. M. Thompson, M. Heuker, H. Hoekstra, C. A. Dillen, R. V. Ortines, A. G. Ashbaugh, J. E. Pickett, M. D. Linssen, N. M. Bernthal, K. P. Francis, G. Buist, M. van Oosten, G. M. van Dam, D. L. J. Thorek, L. S. Miller, J. M. van Dijl. Noninvasive optical and nuclear imaging of Staphylococcus-specific infection with a human monoclonal antibody-based probe

    Virulence, vol. 9, 2018, pp. 262-272
    

40. K. E. Mayer, S. Mall, N. Yusufi, D. Gosmann, K. Steiger, L. Russelli, H. O. Bianchi, S. Audehm, R. Wagner, E. Bräunlein, A. Stelzl, F. Bassermann, W. Weichert, W. Weber, M. Schwaiger, C. D\'Alessandria, A. M. Krackhardt. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target

    Theranostics, vol. 8, 2018, pp. 6070-6087
    

41. K. E. Henry, T. R. Dilling, D. Abdel-Atti, K. J. Edwards, M. J. Evans, J. S. Lewis. Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with (18)F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer

    J Nucl Med, vol. 59, 2018, pp. 51-57
    

42. H. M. Gibson, B. N. McKnight, A. Malysa, G. Dyson, W. N. Wiesend, C. E. McCarthy, J. Reyes, W. Z. Wei, N. T. Viola-Villegas. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy

    Cancer Res, vol. 78, 2018, pp. 5706-5717
    

43. R. Chekol, V. R. Solomon, E. Alizadeh, W. Bernhard, D. Fisher, W. Hill, K. Barreto, J. F. DeCoteau, A. C. Parada, C. R. Geyer, H. Fonge. ⁸⁹Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I

    Oncotarget, vol. 9, 2018, pp. 17117-17132
    

44. I. J. G. Burvenich, S. Parakh, F. T. Lee, N. Guo, Z. Liu, H. K. Gan, A. Rigopoulos, G. J. O\'Keefe, S. J. Gong, Y. W. Goh, H. Tochon-Danguy, F. E. Scott, M. Kotsuma, K. Hirotani, G. Senaldi, A. M. Scott. Molecular imaging of T cell co-regulator factor B7-H3 with ⁸⁹Zr-DS-5573a

    Theranostics, vol. 8, 2018, pp. 4199-4209